glp 1 agonism GLP-1R and Diabetes new glp 1 agonist Are
Description
This means we have a lot of evidence about both their effectiveness as well as their long-term risks.1 To finally arrive at a brisk answer to the above question: Yes, GLP-1 drugs seem like the real deal, even if the specifics of their broad benefits remain uncertain
Compelling epidemiological evidence links metformin prescription to the reduced risks of AD and PD, indicating the potential repurposing of this widely used diabetes drug for neuroprotection
Metabolism 96 (1), 229236
0.76 (95% CI, 0.73-0.79) for exenatide
[DOI] [PubMed] [Google Scholar] 65.Salim H
W., Grard, A
